Chronic Phase Chronic Myeloid Leukemia

Also known as: Chronic phase chronic myeloid leukaemia / Leukemia, Myeloid, Chronic-Phase / Myeloid leukemia, chronic / Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Chronic myeloid leukemia / CML / Chronic myelogenous leukaemia / Chronic myelocytic leukaemia / Leukemia myelocytic chronic / Chronic myelogenous leukemia / Leukaemia myelocytic chronic / Chronic granulocytic leukemia / Leukaemias chronic myeloid / Chronic myelocytic leukemia / Chronic granulocytic leukaemia / Chronic myeloid leukaemia / Myeloid leukaemia, chronic

DrugDrug NameDrug Description
DB04868NilotinibNilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). In June 2006, a Phase I clinical trial found nilotinib has a relatively favorable safety profile and shows activity in cases of CML resistant to treatment with imatinib (Gleevec®), another tyrosine kinase inhibitor currently used as a first-line treatment. [Wikipedia]
DB08901PonatinibPonatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.
DrugDrug NameTargetType
DB04868NilotinibTyrosine-protein kinase ABL1target
DB04868NilotinibMast/stem cell growth factor receptor Kittarget
DB04868NilotinibCytochrome P450 2D6enzyme
DB04868NilotinibCytochrome P450 2C8enzyme
DB04868NilotinibCytochrome P450 2C9enzyme
DB04868NilotinibCytochrome P450 3A4enzyme
DB04868NilotinibMultidrug resistance protein 1transporter
DB04868NilotinibATP-binding cassette sub-family G member 2transporter
DB04868NilotinibUDP-glucuronosyltransferase 1-1transporter
DB04868NilotinibCytochrome P450 2B6enzyme
DB04868NilotinibSolute carrier organic anion transporter family member 1B1transporter
DB08901PonatinibTyrosine-protein kinase ABL1target
DB08901PonatinibBreakpoint cluster region proteintarget
DB08901PonatinibMast/stem cell growth factor receptor Kittarget
DB08901PonatinibProto-oncogene tyrosine-protein kinase receptor Rettarget
DB08901PonatinibAngiopoietin-1 receptortarget
DB08901PonatinibReceptor-type tyrosine-protein kinase FLT3target
DB08901PonatinibCytochrome P450 3A4enzyme
DB08901PonatinibCytochrome P450 2C8enzyme
DB08901PonatinibCytochrome P450 2D6enzyme
DB08901PonatinibCytochrome P450 3A5enzyme
DB08901PonatinibMultidrug resistance protein 1transporter
DB08901PonatinibATP-binding cassette sub-family G member 2transporter
DB08901PonatinibFibroblast growth factor receptor 1target
DB08901PonatinibFibroblast growth factor receptor 2target
DB08901PonatinibFibroblast growth factor receptor 3target
DB08901PonatinibFibroblast growth factor receptor 4target
DB08901PonatinibTyrosine-protein kinase Lcktarget
DB08901PonatinibProto-oncogene tyrosine-protein kinase Srctarget
DB08901PonatinibTyrosine-protein kinase Lyntarget
DB08901PonatinibVascular endothelial growth factor receptor 2target
DB08901PonatinibPlatelet-derived growth factor receptor alphatarget
DrugDrug NamePhaseStatusCount
DB04868Nilotinib1Active Not Recruiting1
DB08877Ruxolitinib1Active Not Recruiting1
DB04868Nilotinib1 / 2Recruiting1
DB08877Ruxolitinib1 / 2Recruiting1
DB01254Dasatinib2Active Not Recruiting2
DB00619Imatinib2Active Not Recruiting1
DB08877Ruxolitinib2Not Yet Recruiting1
DB04868Nilotinib3Active Not Recruiting1
DB06300Ponatinib3Active Not Recruiting1
DB08901Ponatinib3Active Not Recruiting1